CRI Awards $19 Million in Cancer Immunotherapy Grants
July 22, 2014 |
In fiscal year 2014 (July 1, 2013, to June 30, 2014), the Cancer Research Institute (CRI) awarded more than $19 million to explore the immune system and how it can be harnessed to conquer cancer.
The awards include:
26 awards for promising postdoctoral fellows who are bringing creative new insights and perspectives to the field
12 grants for the Clinic and Laboratory Integration Program (CLIP), which provides two years of support for translational laboratory investigation
3 Clinical Accelerator grants, including a clinical trial of an anti-PD-L1 immunotherapy in advanced brain cancer and an anti-PD-L1 antibody and a novel TLR8 agonist in ovarian cancer
With this support, CRI scientists are shedding light on some of the most important questions in cancer immunology, such as the role of inflammation in cancer development and progression, normalization of the tumor microenvironment to improve treatments, and the role of tumor oncogenes and how they are involved in immune evasion. Through coordinated, early stage clinical trials, CRI investigators are also laying significant groundwork for the design of safe and powerful new immunotherapies for cancer. Together, these studies have implications for nearly every cancer type, including melanoma, breast, lung, colorectal, ovarian, brain, leukemia, lymphoma, pancreatic, kidney, liver, and prostate cancers.